XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT

XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.07.2025

The following instruments on Boerse Frankfurt do have their last trading day on 24.07.2025
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.07.2025

ISIN Name
DE000A1R0XXX EKOSEM-AGRAR AG 12/27
DK0060036XXX SPAR NORD BANK NAM. DK 10
US15117N6XXX IMUNON INC. DL-,01
US92511W1XXX VERRICA PHARMAC. DL-,0001
XS1813504XXX SIGMA HOLDCO 18/26 REGS
XS1827819XXX SON.ESP.F.2 18/37 A1
XS1827820XXX SON.ESP.F.2 18/37 A2
XS1917880XXX SON.ESP.F.2 18/37 A3
XS1917881XXX SON.ESP.F.2 18/37 A4
XS2198191XXX TK ELEV. HOL REGS 20/28

SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen

Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!

Hier klicken

Zeit	Aktuelle Nachrichten
23.06.	Imunon, Inc.: IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification	On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer... ► Artikel lesen
22.06.	Imunon, Inc.: IMUNON to Present at the Life Sciences Investor Forum on June 25th
17.06.	Imunon, Inc. - S-8, Securities to be offered to employees in employee benefit plans
16.06.	Imunon, Inc. - 8-K, Current Report
04.06.	IMUNON announces $10M cash financing

Zeit

Aktuelle Nachrichten

23.06.

Imunon, Inc.: IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer...
► Artikel lesen

22.06.

Imunon, Inc.: IMUNON to Present at the Life Sciences Investor Forum on June 25th

17.06.

Imunon, Inc. - S-8, Securities to be offered to employees in employee benefit plans

16.06.

Imunon, Inc. - 8-K, Current Report

04.06.

IMUNON announces $10M cash financing

Zeit	Aktuelle Nachrichten
20.05.	Resurs Bank AB (publ): Resurs Bank acquires Danish loan portfolio from Spar Nord Bank
20.05.	Resurs Holding AB (publ): Resurs Bank acquires Danish loan portfolio from Spar Nord Bank	Resurs Bank acquires a Danish loan portfolio of DKK 480 million from Spar Nord Bank, strengthening the bank's position in the Danish market. The acquired portfolio comprises consumer loans and sales... ► Artikel lesen
01.04.	Decisions of extraordinary General Meeting of Spar Nord Bank A/S	Company announcement no. 07 To Nasdaq Copenhagen Extraordinary General Meeting of Spar Nord Bank A/S on 1 April 2026 At the Extraordinary General Meeting of Spar Nord Bank A/S held on Wednesday 1... ► Artikel lesen
26.03.	Annual general meeting of Spar Nord Bank A/S	Company announcement no. 06 Annual general meeting of Spar Nord Bank A/S At Spar Nord Bank A/S's annual general meeting held on Thursday 26 March 2026: The Annual Report 2025, including the proposal... ► Artikel lesen
17.03.	Spar Nord Bank A/S: Notice of extraordinary general meeting

Zeit

Aktuelle Nachrichten

20.05.

Resurs Bank AB (publ): Resurs Bank acquires Danish loan portfolio from Spar Nord Bank

20.05.

Resurs Holding AB (publ): Resurs Bank acquires Danish loan portfolio from Spar Nord Bank

Resurs Bank acquires a Danish loan portfolio of DKK 480 million from Spar Nord Bank, strengthening the bank's position in the Danish market. The acquired portfolio comprises consumer loans and sales...
► Artikel lesen

01.04.

Decisions of extraordinary General Meeting of Spar Nord Bank A/S

Company announcement no. 07 To Nasdaq Copenhagen Extraordinary General Meeting of Spar Nord Bank A/S on 1 April 2026 At the Extraordinary General Meeting of Spar Nord Bank A/S held on Wednesday 1...
► Artikel lesen

26.03.

Annual general meeting of Spar Nord Bank A/S

Company announcement no. 06 Annual general meeting of Spar Nord Bank A/S At Spar Nord Bank A/S's annual general meeting held on Thursday 26 March 2026: The Annual Report 2025, including the proposal...
► Artikel lesen

17.03.

Spar Nord Bank A/S: Notice of extraordinary general meeting

Zeit	Aktuelle Nachrichten
23.06.	H.C. Wainwright reiterates Verrica stock rating on trial progress
22.06.	Verrica: Erster US-Patient in Phase-3-Studie für Warzenmittel behandelt
22.06.	Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts	- Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global... ► Artikel lesen
09.06.	Verrica Pharmaceuticals Inc. - 8-K, Current Report
13.05.	Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call

Zeit

Aktuelle Nachrichten

23.06.

H.C. Wainwright reiterates Verrica stock rating on trial progress

22.06.

Verrica: Erster US-Patient in Phase-3-Studie für Warzenmittel behandelt

22.06.

Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts

- Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan - - Verrica maintains ownership of global...
► Artikel lesen

09.06.

Verrica Pharmaceuticals Inc. - 8-K, Current Report

13.05.

Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call